The Cloudbreak immunotherapy discovery platform is a fundamentally new approach for the treatment of infectious disease that, in a single molecule, pairs potent antimicrobials with agents that direct the immune system to attack microbial pathogens.
Cloudbreak
Immunotherapy Discovery Platform
Cloudbreak
Immunotherapy Discovery Platform
The Cloudbreak immunotherapy discovery platform is a fundamentally new approach for the treatment of infectious disease that, in a single molecule, pairs potent antimicrobials with agents that direct the immune system to destroy microbial pathogens.
Cloudbreak Platform Overview
The design of the Cloudbreak immunotherapy platform recognizes that most infectious disease is due to a deficiency in the function of the immune system to address potentially life-threatening infections. Our Cloudbreak candidates are potent, long acting, and bi-specific biologics designed to simultaneously target and destroy the pathogen while directing and enhancing the immune response at the site of infection.
Cloudbreak Candidates Attack Pathogens via Two Routes
- Targeting Moiety (TM): Novel and highly potent small molecule(s) that bind surface targets on the pathogens to destroy them or inhibit replication.
- Effector Moiety (EM): Fragment crystallizable (Fc) region of human IgG1 antibodies. Fcs are natural components of the human adaptive immune system required for immune cell engagement and pathogen clearance at the site of infection.
Our candidates are bispecific – the TM is designed to bind to a surface target on the pathogen and neutralize it, and the EM binds to specific receptors on immune effector cells. The Cloudbreak immunotherapy platform is similar to certain cancer immunotherapies in that it directs the immune system to destroy the desired target.
